Rocbrutinib

DRUG7 trials

Conditions

B-cell Non-Hodgkin LymphomaCLLCLL (Chronic Lymphocytic Leukemia)CLL / SLLCLL ProgressionCLL, RefractoryCLL, RelapsedDLBCL

Phase 1

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Active, not recruitingNCT06251180

Guangzhou Lupeng Pharmaceutical Company LTD.B-cell Non-Hodgkin Lymphoma

Start: 2024-04-10End: 2029-12-31Target: 112Updated: 2026-09-11

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

RecruitingNCT07570017

Guangzhou Lupeng Pharmaceutical Company LTD.DLBCL

Start: 2026-06-25End: 2028-07-31Target: 42Updated: 2026-09-10

Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Active, not recruitingNCT05716087

Guangzhou Lupeng Pharmaceutical Company LTD.Mantle Cell Lymphoma (MCL)

Start: 2023-02-21End: 2026-06-30Target: 62Updated: 2026-01-15

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

RecruitingNCT07189065

Guangzhou Lupeng Pharmaceutical Company LTD.Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2025-11-27End: 2028-12-31Target: 150Updated: 2025-12-16

A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis

RecruitingNCT07776743

Guangzhou Lupeng Pharmaceutical Company LTD.Relapsing-remitting Multiple Sclerosis (RRMS)

Start: 2026-08-01End: 2028-12-01Target: 30Updated: 2026-08-20

Phase 3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

RecruitingNCT07342478

Newave Pharmaceutical IncCLL, CLL (Chronic Lymphocytic Leukemia), CLL Progression +5

Start: 2026-04-23End: 2030-07-30Target: 306Updated: 2026-08-11

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

RecruitingNCT07377578

Guangzhou Lupeng Pharmaceutical Company LTD.Mantle Cell Lymphoma

Start: 2026-02-05End: 2033-01-30Target: 394Updated: 2026-02-06

Related Papers

ROCK-2: An ongoing open-label, randomized, multicenter phase 2 study of rocbrutinib versus investigator's choice of therapy in patients with R/R non-GCB DLBCL.

Journal of Clinical Oncology2026-05-28

ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Journal of Clinical Oncology2026-05-28

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood2025-11-03

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood2024-11-05

An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.

Journal of Clinical Oncology2024-06-01

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood2023-11-02